Our additional research and development programs relate to a proprietary opioid-sparing anesthetic and synthesis of novel compounds and new chemical entities, or NCEs. Dr. Joseph (Yossi) Tam, who is a member of our scientific advisory board, heads the MCCR.
Proprietary Opioid-Sparing Anesthetic
In collaboration with Dr. Alexander Binshtok of Hebrew University, we are evaluating the CBD-mediated activation of nociceptive, transient receptor potential cation channels, or TRPV1 and TRPA1 channels, for painless pain-selective anesthesia.
Synthesis of Novel Cannabinoids
In collaboration with Dr. Dmitry Tsvelikhovsky of Hebrew University, we are pursuing two programs seeking to synthesize novel cannabinoids: cannabinoid-based dual-action compounds and novel chemical derivatives based upon the molecular structure of existing cannabinoids. Both of these programs are intended to provide us with a series of proprietary NCEs for evaluation as potential drug candidates.
All of our drug candidates targeting the ECS will be synthetically produced and we intend to pursue FDA approval, as well as other U.S. and non-U.S. regulatory approvals for such drug candidates.